重组凝血因子VIIa与血肿扩大位移:4项随机对照试验的汇总分析
本研究对4项评估重组凝血因子VIIa(rFVIIa)80 μg/kg与安慰剂对照的随机对照试验进行个体患者数据汇总分析,采用血肿扩大位移(HES)分析评估止血治疗的生物学效应。主要分析纳入721例患者,24小时时rFVIIa组36%(134/369)无血肿扩大,安慰剂组25%(88/352);rFVIIa与血肿增长停滞的关联在基线血肿体积较大患者中更为明显,但在全部治疗患者中均可观察到。
要点
- 24小时无血肿扩大比例:rFVIIa组36%(134/369) vs 安慰剂组25%(88/352)。
- 显著扩大(≥6 mL)在rFVIIa治疗者中减少10%,校正共同比值比(acOR)0.57(95% CI 0.43-0.75)。
- 基线血肿体积≥20 mL者绝对HES差异更明显(acOR 0.48 vs <20 mL acOR 0.67,交互P=0.02)。
核心结论
- rFVIIa与血肿增长停滞的关联在基线体积较大的患者中最为明显,但在全部治疗患者中均可观察到。
研究设计与样本
- 对4项评估rFVIIa 80 μg/kg与安慰剂对照的随机对照试验的个体患者数据进行汇总分析。
- 主要分析纳入721例患者。
主要发现
- 24小时时,rFVIIa组36%(134/369)无血肿扩大,安慰剂组25%(88/352)无血肿扩大。
- 显著扩大(≥6 mL)在rFVIIa治疗者中减少10%,校正共同比值比(acOR)0.57(95% CI 0.43-0.75)。
- 百分比变化分析同样显示整个扩大谱系上的位移(acOR 0.61,95% CI 0.47-0.80)。
- 两组中轻度至中度扩大见于38%至47%的患者,取决于所用阈值。
- 基线血肿体积≥20 mL者绝对HES差异更明显(acOR 0.48,95% CI 0.30-0.76) vs <20 mL(acOR 0.67,95% CI 0.47-0.95),交互P=0.02;发病至治疗≤2小时与>2小时无治疗交互(acOR 0.42,95% CI 0.19-0.91 vs acOR 0.59,95% CI 0.44-0.79;交互P=0.30)。
关键数值与推荐
- HES采用绝对增长阈值(≤0/<6/≥6 mL)和百分比体积变化的五分位数分层。
- 治疗与HES的关系采用比例优势模型评估。
- 亚组差异基于基线体积(≥或<20 mL)和发病至治疗时间(≤或>2小时)探索,并检验交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hematoma expansion shift (HES) analysis can be used to assess the biological effect of a hemostatic therapy for intracerebral hemorrhage. In this study, we applied HES analysis to individual patient data from 4 randomized controlled trials evaluating rFVIIa (recombinant factor VIIa) 80 μg/kg to placebo. METHODS: We generated polychotomous strata of HES using absolute growth thresholds (≤0/<6/≥6 mL) and quintiles of percent volume change. The relationship between treatment and HES was assessed using proportional odds models. Differences in subgroups based on baseline volume (≥ or <20 mL), and time from symptom onset to treatment (≤ or >2 hours) were explored with testing for interactions. RESULTS: The primary analysis included 721 patients. At 24 hours, 36% (134/369) of rFVIIa-treated patients exhibited no hematoma expansion as compared with 25% of placebo (88/352)-treated patients. Significant expansion (≥6 mL) was reduced by 10% in those treated with rFVIIa-(adjusted common odds ratio [acOR], 0.57 [95% CI, 0.43-0.75]). An examination of percent change similarly showed a shift across the spectrum of expansion (acOR, 0.61 [95% CI, 0.47-0.80]). In both groups, mild-to-moderate expansion was observed in 38% to 47% of patients, depending on the threshold used. Differences in absolute HES between the rFVIIa and placebo groups were more pronounced in patients with baseline hemorrhage volumes ≥20 mL (acOR, 0.48 [95% CI, 0.30-0.76] versus <20 mL: acOR, 0.67 [95% CI, 0.47-0.95]; Pinteraction=0.02). No treatment interaction in patients treated within 2 or after 2 hours from onset was observed (acOR, 0.42 [95% CI, 0.19-0.91 versus >2 hours: acOR, 0.59 [95% CI, 0.44-0.79]; Pinteraction=0.30). CONCLUSIONS: The association between rFVIIa and hematoma growth arrest is most pronounced in patients with larger baseline volumes but is evident across the full spectrum of treated patients.
引用
- Yogendrakumar V, Mayer SA, Steiner T, et al. Exploring Hematoma Expansion Shift With Recombinant Factor VIIa: A Pooled Analysis of 4 Randomized Controlled Trials. Stroke. 2023. PMID: 37805927. doi:10.1161/STROKEAHA.123.043209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。